Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arvind Shah

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Current Medical Research and Opinion|May 20, 2006
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysisLeiv Ose, Arvind Shah, Michael J Davies, et al.
Journal of Clinical Lipidology|February 20, 2016
Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapyW Virgil Brown, JoAnne M Foody, Franklin J Zieve, et al.
Clinical Therapeutics|July 25, 2006
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trialsTheodore Feldman, Michael Davidson, Arvind Shah, et al.
Diabetes Care|February 17, 2012
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trialJohn R Guyton, Sergio Fazio, Adeniyi J Adewale, et al.
The American Journal of Cardiology|January 27, 2009
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapyThomas A Pearson, Christie M Ballantyne, Enrico Veltri, et al.
Lipids in Health and Disease|November 6, 2010
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potencyMargus Viigimaa, Helena Vaverkova, Michel Farnier, et al.
Lipids in Health and Disease|December 2, 2010
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?Harold Bays, Scott Conard, Lawrence A Leiter, et al.
Eye (London, England)|March 2, 2026
Predictive factors for visual acuity in diabetic macular oedema: lessons for clinical practice learned from deferring intravitreal injections under the COVID-19 pandemicMarcela Bohn, Jose Carlo M Artiaga, Tjebo Heeren, et al.
Clinical Biochemistry|February 26, 2011
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary diseaseHelena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Atherosclerosis|April 28, 2015
Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patientsOlivier Descamps, Joanne E Tomassini, Jianxin Lin, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Current Medical Research and Opinion|May 20, 2006
Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysisLeiv Ose, Arvind Shah, Michael J Davies, et al.
Journal of Clinical Lipidology|February 20, 2016
Inverse relationship between high-density lipoprotein cholesterol raising and high-sensitivity C-reactive protein reduction in older patients treated with lipid-lowering therapyW Virgil Brown, JoAnne M Foody, Franklin J Zieve, et al.
Clinical Therapeutics|July 25, 2006
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trialsTheodore Feldman, Michael Davidson, Arvind Shah, et al.
Diabetes Care|February 17, 2012
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trialJohn R Guyton, Sergio Fazio, Adeniyi J Adewale, et al.
The American Journal of Cardiology|January 27, 2009
Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapyThomas A Pearson, Christie M Ballantyne, Enrico Veltri, et al.
Lipids in Health and Disease|November 6, 2010
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potencyMargus Viigimaa, Helena Vaverkova, Michel Farnier, et al.
Lipids in Health and Disease|December 2, 2010
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?Harold Bays, Scott Conard, Lawrence A Leiter, et al.
Eye (London, England)|March 2, 2026
Predictive factors for visual acuity in diabetic macular oedema: lessons for clinical practice learned from deferring intravitreal injections under the COVID-19 pandemicMarcela Bohn, Jose Carlo M Artiaga, Tjebo Heeren, et al.
Clinical Biochemistry|February 26, 2011
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary diseaseHelena Vaverkova, Michel Farnier, Maurizio Averna, et al.
Atherosclerosis|April 28, 2015
Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patientsOlivier Descamps, Joanne E Tomassini, Jianxin Lin, et al.
Pageof 4